{"name":"Monte Rosa Therapeutics, Inc","slug":"monte-rosa-therapeutics-inc","ticker":"","exchange":"","domain":"monterosa.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxNVXBJS1RiY3BOY3BUOVhCZTFKdkJIYWRxdFlNVWhkV1gwWlpsd0dFTXlXVUlHZEltM2s4MmNReWZjNElCRTM1VktLaDNzMG5SRDU3NXBrdXJrcWppbTB0QmNHWnA5Z3hjUWFueXJCbDRrQmg2Q0U0MjBzWFc5UEpsdHJvS1BWR3lLblNQd1V0TnZZdjd3aXlXMDQtY21kVVllMUJYREgxQTVhOXY3a0JOWklGelVBNlZvQ1dlVkdNYnl3M1BMd2h0WlhLbk9hSUtEU3R1OE9sVmpTVTdCVlB5emhwQUpWLWUx?oc=5","date":"2026-03-19","type":"deal","source":"The Globe and Mail","summary":"Wells Fargo Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE) - The Globe and Mail","headline":"Wells Fargo Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPLWVmQ2VhTWY1Y05QZE5reVpzdHBGWEI5UFNyazhtcS1BczFxbGZmMlY4a1RtU01Rd0ZsZjY2MUN3SU1jMnAtdjBRczhHTzhrVjllTVc0TkhsazhwRnIxMGtFekx2YzNaNXdTeVhQSDRmWEtFZkRiYk5qQ2xBdDVocnV1ZWtyYXdyM3EyeHhGWHV0NXE3bnJ0aQ?oc=5","date":"2026-01-08","type":"trial","source":"Finviz","summary":"GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug - Finviz","headline":"GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOaUlyT19Fby04ZTk0UmlkMVNxWHFUa3Q4RVlCbnNTeU1tTTYzNFZRXzZacWtKSXFXWExpRlN3azcwQXhmYXFrNE1GaTZudC04a09oUEc3dFRFdjMzOFdTQWYzc2xnTGVyM1RMVVdGM3JMYlRHVGN2Z1RBNnhUMFZhZ1oyZnpqeEFmNWs4ZDRBZDIxYU9malVKX1ZfM1BucW9VMV9XTFpyMjRUYXNGVzlTMHRGelBDdFNt?oc=5","date":"2026-01-07","type":"pipeline","source":"Investing.com","summary":"Monte Rosa Therapeutics launches $200 million public offering - Investing.com","headline":"Monte Rosa Therapeutics launches $200 million public offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxPVUNQUmNUT05Ob1lHMGoyY3lfOVhOQTRCU2lNX3BNdFd2TmhQM3ZscjJwUndRdHFBNThhQzAzNzVwdWVjM0VfTU45bzRuZE9MRXFjcUhRM3AtZ29wcHFGaVZna0hzMGg1ZUZVLXpIUm5UZTRRdV9iMWxxdWVhOVJJNEFSbTlRbEtUTXYtUmVyOU8wbnh6SWFuUWt2SmgwV2hMSnBqcnBLSllOdFc1akxETnRTaEEyVmdVaHNKcUFvWHBSZUg2ZlFvdm44U29CTnhrN2VOMkZRM0hVNVctdm42S0t6dE90a0hfY2EycmdxQW9qQkNjNmk5dlQ5V1B4c1F2MGtkYVJqaDF3a2VKWGtWQnVHeHJ0WEtBcHR0Um1zZXB4M094VXZrYlF5bG5jeGlWd3B4enZycEIxWGs?oc=5","date":"2026-01-07","type":"trial","source":"GlobeNewswire","summary":"Monte Rosa Therapeutics Announces Positive Interim Phase 1 - GlobeNewswire","headline":"Monte Rosa Therapeutics Announces Positive Interim Phase 1","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQb0I4ejNFTUFTZmI1QmtkRDFIc1FzaU12U0tESC1vcHRXMjIyV21YVm1mOGs1UHZVWHUxdTFDVWhkSmVhWFlCclUwTUQ1TElueVpjQnpDSWhsNkJHN0ZmX0VqZ3MxalhhU21vbDBnQmlLTDVFTjU4QTZJYWJnTllleFhKZW1BOXNYMkR4SWxrUXdsaXJQcU9SMEpxaWNnR0YzQV9USjN2UUJtTHlEZlZFaWloOW1PNjF1RE10ZQ?oc=5","date":"2026-01-06","type":"trial","source":"Stock Titan","summary":"Early trial results for a new drug targeting heart disease risk go public - Stock Titan","headline":"Early trial results for a new drug targeting heart disease risk go public","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQS3paMElqVEU5bmQ1VVhadkxZTDZOVHdnQmJfdlVuVjZRMlBZNlVsaFpNSVU4c0RlaWxVUzd2dkVqb3VfeXFGckxlMnE0dEZnM3Z3c0tEU2pvUVB4Smp4enUyTDFDYzRGWEY0NXMzdXY2MEk2NlpHSGF3VUxxdXBJWm5sRU1iUnpBRjJaU1d3UjBGRzJia0JnYmlFWEI5Zw?oc=5","date":"2025-11-30","type":"pipeline","source":"Seeking Alpha","summary":"Monte Rosa: Looking Mispriced After Big Pharma Validation (NASDAQ:GLUE) - Seeking Alpha","headline":"Monte Rosa: Looking Mispriced After Big Pharma Validation (NASDAQ:GLUE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPcU1vQkdtY05jMWY3SUI5OTFyRC12Rm8yZ0RZckEtUlFNSVliVEVGcVowdUlMTlI0NHQzRF9FdGg5aGdnNndIWVYzN0FaQnNDcG1rR3VZTkg5YTNNSXRtVHlHUjNHb3NfSUNOVmJ3cGM4UElaemhRSEt3QXZ3NkVScVNuOWF2U0pWUjhYSEtHZ2FVMDRvN1A1cmFjUVlQLU5hVGI4c2d4TGM0bGw0UGM0TGVCRUprazlhbmZBbw?oc=5","date":"2025-09-16","type":"deal","source":"European Biotechnology Magazine","summary":"Monte Rosa Therapeutics and Novartis agree on second billion-dollar deal - European Biotechnology Magazine","headline":"Monte Rosa Therapeutics and Novartis agree on second billion-dollar deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxNdG9FYUFjUVpGNWRwNFc5VjJTNG9BdTU5aUdOSzJ5WUxaQkJMRks3eGxPTktTcGxHQUdRVmd0cllIUV9aWmtzUlZHVUN2dV8xajF3V0FkVFgteERsN2JudEl2V3dKX3V0b1gtVmxnX05HNEVnTDY3b28tQ3V0ZGg2VmItbEQtX21xZjVlaExsaUlPa3RwMkpZSXNIbi1QY09GOWR0SHRYMF90US0xNl9pVGw0bV9FdnhqMS1wWWJreTJoRThoT2JUMkstVVY2ZWlzd2hnYUUwOXY3ZXg5?oc=5","date":"2025-09-15","type":"deal","source":"Reuters","summary":"Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics - Reuters","headline":"Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQSm9LZFkwY09NS0ZkZEVsQkFfellMdUUyYzNzbDY1TVZwNkd1NWlsUzlNZGtQWWlmb3g4T09JZDR1clp0b0ZsUDRyNFpoVkRGc1dCbWtCWWRYWl9uMkFvZU1UaVEtNE5odC0yVjd4YmtpYkt2bzh3NkRuRnRaYndOMS1FRkNnOTd5alRKek1hMVZoU3lsVVlBb0djX0JqTnRrenVLR2xBdWp0M3BSSnA1SkpIMlFvRDFHSXZTbw?oc=5","date":"2025-09-15","type":"deal","source":"Pharmaceutical Technology","summary":"Novartis returns to Monte Rosa for second time in a year with $5.7bn deal - Pharmaceutical Technology","headline":"Novartis returns to Monte Rosa for second time in a year with $5.7bn deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOWFduejkzQ3U2VkczdEhBVFk2UkFLTzJIeEd2VlBKUUtjWmFBbVU3bUh3N0dJVkdQbzNscEFsRFFrRklfTWRYMmI4aWFPMjJfSVZ5alJLVXJLbzZERXhWLUhjUTZma19wVS1rUmk1VXc3YW1NbnZfNWNjTXQ2OHFaSEREZ0RCYmItMzltX1lGdlJENklkbDhyX1kyXzNFYl9NbEZpbGZZdzUzRUNkUS0tcA?oc=5","date":"2025-09-15","type":"deal","source":"BioPharma Dive","summary":"Novartis dives deeper into protein degraders with second Monte Rosa deal - BioPharma Dive","headline":"Novartis dives deeper into protein degraders with second Monte Rosa deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE0tQTZpLVJMaWRYekVIcWdKUXBKWkdNUHZYMndPQlY0bkJCQVAtY1ZuUl9LcUVQTEY0RkdMeV82VW9zUDRmUnk3T1ZRTkRZOWJKUVFN?oc=5","date":"2025-09-15","type":"deal","source":"FirstWord Pharma","summary":"Novartis inks a second degrader-focused deal with Monte Rosa - FirstWord Pharma","headline":"Novartis inks a second degrader-focused deal with Monte Rosa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNeWp5MWN2dFpTOGZoUlQtS0tmZzVXOTRFZkZycmJQZTJQZi1ENG5peWppbkpoaFZUVnVtMXU3TkNfaEljUzcwUm5sa2VtbzZXN3lmeVdPUUdnaUxZdVZkRUlvRmw4Znl5QnJYN3RSSVplV21GbnpoQUFnem9uTlpnaTNCUlhpUDNYYmVLNGxNd05tbFNrTzlaVzhidHNtQjZFeEZJd05fM0IxQkRlZ0dnRHhxVlBpXzFuUDJR?oc=5","date":"2025-09-15","type":"deal","source":"Contract Pharma","summary":"Monte Rosa & Novartis Partner to Develop Immune-Mediated Disease Treatments - Contract Pharma","headline":"Monte Rosa & Novartis Partner to Develop Immune-Mediated Disease Treatments","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}